[1] 陆再英,钟南山.内科学[M].7 版.北京:人民卫生出版社,2008:274.
[2] Khuseyinova N,Koenig W.Predicting the risk of cardiovascular disease:where does lipoprotein-associated phospholipase A(2) fit in?[J].Mol Diagn Ther,2007,11(4):203-217.
[3] Papathanasiou AI,Lourida ES,Tsironis LD,et al.Short-and long-term elevation of autoantibody titers against oxidized LDL in patients with acute corcnay syndromes.Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment[J].Atherosclerosis,2008,196(1):289-297.
[4] Tselepis AF,Rizzo M,Goudevenos IA.Therapeutic modulation of lipoprotein-associated phospholipase A2(Lp-PLA2)[J].Curr Pharm Des,2011,17(33):3656-3661.
[5] Ronti T,Lupattelli G,Mannarino E.The endocrine function of adipose tissue:an update[J].Clin Endocrinol(Oxf),2006,64(4):355-365.
[6] 刘更夫,左华泽,骆明波,等.血清视黄醇结合蛋白4水平与动脉粥样硬化危险因素的相关性分析[J].微循环学杂志,2009,19(3):61-63.
[7] 谢玉婷,汪年松.视黄醇结合蛋白4与心血管疾病的研究进展[J/CD].中华临床医师杂志:电子版,2011,5(6):1698-1700.
[8] 张敏,唐荣珍,曹晓江,等.冠心病合并2型糖尿病血清视黄醇结合蛋白4水平与冠状动脉病变程度的相关性研究[J].华西医学,2011,26(12):1818-1821.
[9] 周海艳,岳晓丽,石建华.视黄醇结合蛋白4与老年2型糖尿病视网膜病变的相关性研究[J].蚌埠医学院学报,2013,38(7):803-808.
[10] 洪衡,王明生,王河,等.不同类型急性心肌梗死冠状动脉病变特点的观察[J].中国循环杂志,2007,22(3):187-190.
[11] 时永辉,牛冬梅,吴嘉,等.冠心病患者血清脂蛋白相关磷脂酶A2与氧化低密度脂蛋白水平[J].临床检验杂志,2013,31(2):92-95.